More and more data are being collected on people and in healthcare, patients have to believe that the data being collected is for their good and with the goal of improving their care, said John Frownfelter, MD, FACP, chief medical officer of Jvion.
More and more data are being collected on people and in healthcare, patients have to believe that the data being collected is for their good and with the goal of improving their care, said John Frownfelter, MD, FACP, chief medical officer of Jvion.
Transcript
How can healthcare balance the pros and cons consumers see when they think about all the data being collected on them?
Well, the data is out there. I think there is a sense of the public trust having been violated and at the same time everybody acknowledges—I’ve got a lot of friends, especially younger generation, like “Yeah, they collect it and I don’t care. I have Alexa and I have Google in my home, and I know they’re collecting data on me and I don’t care.”
So, is healthcare data really any different? Or is the fact that we’re using social data that we can get on a patient to improve the care that we’re delivering, is that a bad thing? Or is that a good thing? That’s the kind of question that should be raised and debated, but in general, one of the guiding principles there is beneficence, and the good intention behind having that data in order to render better care is certainly noble.
So, at the end of the day, in healthcare, I think we win the ethical discussion and we are certainly in a better position than say the big industry tech giants that are using it for profit.
Survival Rates in CLL: Targeted Agents vs Fludarabine Combo Therapy Study
April 17th 2024Researchers conducted an analysis of 4 phase 3 trials, covering 2751 patients, to address the potential for targeted agents in younger and physically fit patients who have chronic lymphocytic leukemia (CLL).
Read More
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
Age Alone Is No Barrier to Allo-HCT for AML, Data Indicate
April 17th 2024A new study is among the largest real-world analyses to date to assess trends over time and predictive factors for older patients with acute myeloid leukemia (AML) who received allogeneic hematopoietic cell transplantation (allo-HCT).
Read More
The Biden administration recently launched the Global Health Security Strategy, a new effort to combat the spread of infectious diseases; lawmakers zeroed in on the risks of massive consolidation in health care during the first congressional hearing on the Change Healthcare hack; the FDA recently announced the recall of a pair of heart devices linked to numerous deaths and injuries.
Read More